References
- Massaad MJ, Ramesh N, Geha RF. Wiskott-Aldrich syndrome: a comprehensive review. Ann. N.Y. Acad. Sci. 1285, 26–43 (2013).
- Ariga T. Wiskott-Aldrich syndrome; an x-linked primary immunodeficiency disease with unique and characteristic features. Allergol. Int. 61(2), 183–189 (2012).
- Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78, 635–644 (1994).
- Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr. Opin. Hematol. 12(4), 284–291 (2005).
- Ariga T, Oda N, Yamaguchi K et al. T cell lines from two patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood 97, 2896–2899 (2001).
- Ariga T, Kondoh T, Yamaguchi K et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J. Immunol. 166, 5245–5249 (2001).
- Seymour LW, Thrasher AJ. Gene therapy matures in the clinic. Nat. Biotechnol. 30(7), 588–593 (2012).
- Boztug, K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 360(20), 1918–1927 (2010).
- Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S et al. Gene therapy for primary immunodeficiencies: part 1. Curr. Opin. Immunol. 24, 580–584 (2012).
- Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132–3142 (2008).
- Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198–204 (2010).
- Aiuti A, Bacchetta R, Seger R et al. Gene therapy for primary immunodeficiencies: Part 2. Curr. Opin. Immunol. 24, 585–591(2012).
- Scaramuzza S, Biasco L, Ripamonti A et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. 21, 175–184 (2013).
- Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823 (2009).
- Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).
- Aiuti A, Biasco L, Scaramuzza S et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341(6148), 1233151 (2013).
- Biffi A, Montini E, Lorioli L et al. Therapeutic benefit in metachromatic leukodystrophy by lentiviral hematopoietic stem cell gene therapy. Science 341(6148), 1233158 (2013).